PPL acquires rights from Bristol-Myers

PPL Therapeutics (LSE:PTH) acquired exclusive global rights to BMY's production technology for fibrin I sealants derived from fibrinogen to stop bleeding and seal wounds. PTH will pay royalties on sal...